What drugs does JUBILANT make?

JUBILANT has 8 FDA-approved drugs including DRAX EXAMETAZIME, RUBY-FILL.

What therapeutic areas does JUBILANT focus on?

JUBILANT focuses primarily on Oncology and Respiratory and 1 other therapeutic areas.

Data updated: Nov 8, 2026

JUBILANT

Specialty

JUBILANT is a specialty pharmaceutical company focused on Oncology, Respiratory, Infectious Disease. Key products include DRAX EXAMETAZIME.

1978

Since

Drugs

Trials

New Drugs (2yr)

Modality:

6 Small Molecules

JUBILANT's Key Drugs

JUBILANT's core commercial portfolio centers on DRAX EXAMETAZIME, RUBY-FILL, spanning Oncology and Respiratory — its most strategically important drugs approved in the last 15 years.

DRAX EXAMETAZIME

Immunology

Intra-Abdominal Infection

Approved 2017

RUBY-FILL

Cardiovascular

Coronary Artery Disease

Na+/K+ pump Approved 2016

JUBILANT's Recent FDA Approvals

New NDA/BLA approvals for JUBILANT over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

JUBILANT's Therapeutic Areas

JUBILANT's approved drugs and pipeline span 4 therapeutic areas, led by Oncology and Respiratory, across 0 biologic and 6 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 40%

2 drugs Phase 1: 4

Respiratory 30%

2 drugs

Infectious Disease 15%

1 drugs

Metabolic 15%

1 drugs

JUBILANT's Top Competitors

JUBILANT's closest competitors by therapeutic-area and drug-target overlap include Merck, GSK, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Merck big-pharma

Oncology, Infectious Disease, Metabolic, Respiratory

GSK big-pharma

Respiratory, Infectious Disease, Oncology, Metabolic

Baxter specialty

Infectious Disease, Oncology, Metabolic

Johnson & Johnson big-pharma

Oncology, Infectious Disease, Metabolic

Sanofi big-pharma

Metabolic, Oncology, Infectious Disease